News | December 17, 2023
Dr. Reddy's becomes first Indian pharma company to debut on the DJSI
Dr. Reddy's has been awarded 'Gold Medal' status by EcoVadis
Dr. Reddy's has been awarded 'Gold Medal' status by EcoVadis
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Demonstrate significant bleed reduction in hemophilia A and B
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
NATCO temporarily shut down the operations due to cyclone with flooding/water logging of the factory premises
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Almost 300 million people globally have chronic hepatitis B
Subscribe To Our Newsletter & Stay Updated
